Comparison
Tirzepatide vs Retatrutide
Approved dual agonist versus investigational triple agonist
The key difference
Tirzepatide acts on GIP and GLP-1 receptors. Retatrutide adds a third target, the glucagon receptor.
| Tirzepatide | Retatrutide | |
|---|---|---|
| Class | Dual GIP / GLP-1 receptor agonist | Triple GIP / GLP-1 / glucagon receptor agonist |
| Evidence | FDA-approved drug | Human clinical trials |
| Status | Prescription drug. FDA-approved for specific indications. | Investigational. Not FDA-approved. |
| Also known as | Mounjaro, Zepbound | — |
| Researched for | Weight & metabolism | Weight & metabolism |
| Evidence strength | FDA-approved drug | Human clinical trials |
What else differs
- Tirzepatide is FDA-approved; retatrutide is still in clinical trials.
- Glucagon activity is being studied for its potential to raise energy expenditure and reduce liver fat.
- Retatrutide’s phase 2 results drew wide attention, but long-term safety data does not exist yet.
Bottom line
One is an established medicine; the other is a promising compound that has not finished testing.
Read the research
Tirzepatide on PubMed →
Retatrutide on PubMed →
Educational content, not medical advice. This page does not recommend or dose any substance. Compounds that are not FDA-approved have not been established as safe or effective in people.